+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Pioglitazone"

Insulin Drugs Market Report 2025 - Product Thumbnail Image

Insulin Drugs Market Report 2025

  • Report
  • March 2025
  • 175 Pages
  • Global
From
Type 2 Diabetes Market Report 2025 - Product Thumbnail Image

Type 2 Diabetes Market Report 2025

  • Report
  • March 2025
  • 200 Pages
  • Global
From
From
Type 2 Diabetes Pipeline Analysis Report - Product Thumbnail Image

Type 2 Diabetes Pipeline Analysis Report

  • Report
  • August 2024
  • 150 Pages
  • Global
From
From
Anti-diabetic Drugs Market - Product Thumbnail Image

Anti-diabetic Drugs Market

  • Report
  • January 2024
  • 200 Pages
  • Global
From
From
  • 10 Results (Page 1 of 1)
Loading Indicator

Pioglitazone is a drug used to treat type 2 diabetes, a condition in which the body does not produce enough insulin or does not use insulin properly. It belongs to a class of drugs known as thiazolidinediones, which work by increasing the body's sensitivity to insulin. Pioglitazone is used in combination with diet and exercise to improve glycemic control in adults with type 2 diabetes. It can also be used to reduce the risk of cardiovascular events in adults with type 2 diabetes and established cardiovascular disease. Pioglitazone is a widely used drug in the endocrine and metabolic disorders drug market. It is used to treat type 2 diabetes, a condition that affects millions of people worldwide. Pioglitazone is generally well tolerated and has been shown to improve glycemic control and reduce the risk of cardiovascular events in adults with type 2 diabetes. Some companies in the pioglitazone market include Takeda Pharmaceuticals, Merck & Co., Sanofi, and Eli Lilly. Show Less Read more